The prediction and treatment for intravenous immunoglobulin resistant Kawasaki disease
10.3760/cma.j.issn.1673-4912.2020.09.003
- VernacularTitle:川崎病丙种球蛋白耐药的预测和治疗
- Author:
Wang HUA
1
;
Fangqi GONG
Author Information
1. 浙江大学医学院附属儿童医院 国家儿童健康与疾病临床医学研究中心，杭州 310052
- From:
Chinese Pediatric Emergency Medicine
2020;27(9):650-653
- CountryChina
- Language:Chinese
-
Abstract:
Kawasaki disease(KD) is an acute febrile vasculitis and approximate 10% to 20% children with KD are resistant to initial intravenous immunoglobulin(IVIG) treatment at a dose of 2 g/kg, who are named IVIGRKD.Treatments for IVIGRKD include second dose IVIG, second dose IVIG plus glucocorticoid, single intravenous injection of infliximab, intravenous or oral cyclosporine, subcutaneous injection of Anakinra, intravenous cyclophosphamide, and plasma exchange, etc.No evidence suggests which treatment method is better than the others.Therefore, early prediction and timely identification of IVIGRKD are extremely important.Unfortunately, most of current prediction models are based on the statistical analysis of retrospective data, and due to the discrepancy of region and race, their further application are limited.
